ENTITY
Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (ALNY US)

88
Analysis
Health Care • United States
Alnylam Pharmaceuticals Inc. is an early-stage therapeutics company. The Company is developing technology that can specifically and potently silence disease-causing genes.
more
•26 Jun 2018 15:55

Trade Risks Start to Impact, as China Biotech Ambitions Grow…

Cyclical indicators are softening this month - new orders index for the Philly Fed fell nearly 23 points while Japan’s PMI new export orders...

Logo
311 Views
Share
•05 Jan 2018 09:35

Human Longevity

At KIS capital we try to keep ourselves at the forefront of technology and innovation, attempting to identify which industries may blossom, and...

Share
•28 Nov 2017 16:52

Drugs Evolving Into 'Biological Software' to Boost Moribund Pharma Sector?

The global pharma and biotech sector has underperformed by about four points this year, and five over three years – the divergence with other...

Logo
392 Views
Share
bullish•S&P 500 INDEX
•06 Sep 2017 23:22

U.S. Equity Strategy: Reiterating Biotechs, Gold Miners; Downgrading Financials to Market Weight

Key themes: Downgrading Financials. Given the Sector’s relative deterioration, we are downgrading Financials to market weight. Pockets of strength...

Logo
636 Views
Share
•09 Feb 2017 09:14

Trump Health Effect: What Is Next for the Consumer Health Industry Under Trump's Leadership?

While the US consumer health industry will remain a strong centre for investment, development and technology innovation in 2017 and is expected to...

x